Welcome

OWL is a biotechnology company in the field of Metabolomics with pioneering diagnostics products and unique R&D services for the scientific community.

Metabolomics uncovers metabolic alterations in biological samples and provides an overall picture of human or animal health: The information on complex biochemical processes obtained is highly valuable in drug mechanism and toxicology studies, biomarker discovery and the optimization of biotechnological processes.

OWL´s two business lines stem from our in depth knowledge of metabolomics and liver diseases.

DIAGNOSTIC PRODUCTS:

"OWLiver Test" is the first "in vitro" test for determining steatosis and NASH.
The company also develops diagnostic markers research for high prevalence diseases.

R&D SERVICES:

OWL applies its expertise in metabolomics and lipidomics to provide services to the pharmaceutical, food and cosmetics industries, as well as research centers, biotech companies and CROs.

 

Company introduction

  • OWLiver - information for physicians - how it works
  • owl liver for patients - that is it - benefits - faqs
  • what is metabolomics - get to know owl technology
Events
News

04/22/2021

News

Non-invasive diagnosis products for the different stages of nonalcoholic fatty liver disease
It is estimated that NAFLD affects 20-30% of the Western population and presents a clear association with obesity and diabetes. Fast and early detection of fatty liver is key to preventing the progression of this disease.
In this context, the biotechnology company OWL has developed and patented three in vitro diagnosis tools based on metabolomics: OWLiver, OWLiver F2+ y OWLiver
DM2.

 

OWL is a trading name of
ONE WAY LIVER, S.L
Parque Tecnológico de Bizkaia
Edificio 502 - Planta 0
48160 Derio - Bizkaia - Spain
Phone:
+34 94 431 85 40

With this web OWL intends to provide users with information to better understand their health and their diagnosed illnesses. You should consult with a
qualified physician for diagnosis and for answers to your personal questions/circunstances.
Last update: 04/22/2021

With the collaboration of: